| Literature DB >> 33385359 |
Husam M Salah1, Subhi J Al'Aref1, Muhammad Shahzeb Khan2, Malek Al-Hawwas1, Srikanth Vallurupalli1, Jawahar L Mehta1, J Paul Mounsey1, Stephen J Greene3, Darren K McGuire4, Renato D Lopes5, Marat Fudim6.
Abstract
In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.Entities:
Keywords: Sodium-glucose cotransporter 2 inhibitor; chronic kidney disease; death; dual sodium-glucose cotransporter 1 and 2 inhibitors; heart failure; myocardial infarction; outcomes; stroke; type 2 diabetes mellitus
Year: 2020 PMID： 33385359 DOI： 10.1016/j.ahj.2020.12.007
Source DB: PubMed Journal: Am Heart J ISSN： 0002-8703 Impact factor: 4.749